Home / Market News / $RDHL

$RDHL news and market catalysts

The 8 most recent market catalysts affecting $RDHL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

8 catalysts 2 high impact 6 bullish 0 bearish Pharmaceuticals
Nov 19, 2026 Corporate Catalyst Neutral Impact 55
RedHill Biopharma Highlights Strategic Transformation and Commercial Growth Strategy
RedHill Biopharma's Chief Business Officer participated in an investor segment to discuss the company's strategic transformation and expanded commercial growth strategy. This event…
Oct 19, 2026 Corporate Catalyst Bullish Impact 65
RedHill Biopharma’s Partner University Of Oklahoma Receives $2.9M In Funding From National Cancer Institute To Study, In Clinical Trials, Whether RedHill's Opaganib, Given After CAR T-Cell Therapy, May Help Immune Cells Fight Cancer More Effectively
The University of Oklahoma, a partner of RedHill Biopharma, secured a significant $2.9 million grant from the National Cancer Institute. This funding is specifically allocated to c…
Sep 30, 2026 Corporate Catalyst Neutral Impact 95
Redhill Biopharma H1 2026 EPS $0.00 And Revenue $0.00
Redhill Biopharma (RDHL) has filed an 8-K reporting H1 2026 EPS and revenue of $0.00. This is an extremely unusual and potentially alarming disclosure. While it could be a clerical…
Sep 1, 2026 Corporate Catalyst Bullish Impact 75
RedHill Biopharma Announces Deal To Acquire Global Rebyota And U.S. Clenpiq Commercialization Rights From Ferring For $12M Upfront, Plus Milestones And Tiered Royalties
This headline represents a significant corporate catalyst for RedHill Biopharma, as it directly impacts their product portfolio and potential for future revenue growth. The acquisi…
Aug 31, 2026 Corporate Catalyst Bullish Impact 95
Redhill Biopharma Stock Doubles In One Session — Here's Why
Redhill Biopharma's divestment of Talicia to Apotex for $18 million upfront, with additional milestone payments, is a significant corporate catalyst. This transaction provides imme…
Aug 31, 2026 Corporate Catalyst Bullish Impact 75
Redhill Biopharma shares are trading higher after the company announced the divestment of its Talicia business to a subsidiary of Apotex Health.
This headline signifies a significant corporate catalyst for Redhill Biopharma. The divestment of its Talicia business is likely viewed positively by investors as it could reduce o…
Aug 31, 2026 Corporate Catalyst Bullish Impact 75
Redhill Biopharma Divests Talicia Business To Apotex Health Subsidiary For An Upfront Payment Of $18M Plus Up To An Additional $35M In Potential Sales-based Milestone Payments
Redhill Biopharma has announced the divestiture of its Talicia business to Apotex Health for an immediate $18 million and potential future payments. This transaction is a significa…
Jul 28, 2026 Corporate Catalyst Bullish Impact 75
RedHill Biopharma Says Ebola Outbreak Grows To 3221 Cases, 1407 Deaths; Opaganib Development And Partnership Talks Ongoing With African Medicines Agency, Ugandan Health Ministry
The primary impact of this headline is on RedHill Biopharma (RDHL). The ongoing development and partnership talks for Opaganib in the context of a growing Ebola outbreak present a …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.